NO930059L - O-glykosylert ifn-alfa - Google Patents

O-glykosylert ifn-alfa

Info

Publication number
NO930059L
NO930059L NO93930059A NO930059A NO930059L NO 930059 L NO930059 L NO 930059L NO 93930059 A NO93930059 A NO 93930059A NO 930059 A NO930059 A NO 930059A NO 930059 L NO930059 L NO 930059L
Authority
NO
Norway
Prior art keywords
ifn
glycosylert
alfa
glycosylated
drugs
Prior art date
Application number
NO93930059A
Other languages
English (en)
Norwegian (no)
Other versions
NO930059D0 (no
Inventor
Guenther Adolf
Adolf Himmler
Horst Johann Ahorn
Inge Kalsner
Ingrid Maurer-Fogy
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19904021917 external-priority patent/DE4021917A1/de
Priority claimed from DE19904035877 external-priority patent/DE4035877A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO930059D0 publication Critical patent/NO930059D0/no
Publication of NO930059L publication Critical patent/NO930059L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO93930059A 1990-07-10 1993-01-08 O-glykosylert ifn-alfa NO930059L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19904021917 DE4021917A1 (de) 1990-07-10 1990-07-10 Glykosyliertes ifnalpha
DE19904035877 DE4035877A1 (de) 1990-11-12 1990-11-12 O-glycosyliertes ifn-alfa2
PCT/EP1991/001266 WO1992001055A1 (de) 1990-07-10 1991-07-06 O-glycosyliertes ifn-alpha

Publications (2)

Publication Number Publication Date
NO930059D0 NO930059D0 (no) 1993-01-08
NO930059L true NO930059L (no) 1993-01-08

Family

ID=25894855

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930059A NO930059L (no) 1990-07-10 1993-01-08 O-glykosylert ifn-alfa

Country Status (16)

Country Link
EP (1) EP0538300B1 (enExample)
JP (1) JPH06502987A (enExample)
KR (1) KR930701601A (enExample)
AT (1) ATE104348T1 (enExample)
AU (1) AU650893B2 (enExample)
CA (1) CA2084514A1 (enExample)
CZ (1) CZ386392A3 (enExample)
DE (1) DE59101397D1 (enExample)
DK (1) DK0538300T3 (enExample)
ES (1) ES2063515T3 (enExample)
FI (1) FI930058L (enExample)
HU (1) HUT65846A (enExample)
NO (1) NO930059L (enExample)
PL (1) PL297610A1 (enExample)
SK (1) SK386392A3 (enExample)
WO (1) WO1992001055A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
NZ245771A (en) * 1992-02-07 1994-08-26 New England Medical Center Inc Mammalian gastrin/cholecystokinin b (cck-b) receptor and antagonists
US5541071A (en) * 1992-02-07 1996-07-30 New England Medical Center Hospitals, Inc. Assay for identifying antagonists of gastrin and CCK-B receptors
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US6221582B1 (en) 1994-10-28 2001-04-24 Innogenetics N.V. Polynucleic acid sequences for use in the detection and differentiation of prokaryotic organisms
AU3980497A (en) * 1996-08-14 1998-03-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vector for polynucleotide vaccines
GB9904695D0 (en) * 1999-03-01 1999-04-21 Imp Cancer Res Tech Peptide
WO2001079444A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP2305311A3 (en) * 2001-10-10 2011-07-20 BioGeneriX AG Glycoconjugation of peptides
EP2277888A3 (en) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
CA2519092C (en) 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN101965200B (zh) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
RU2610173C1 (ru) * 2016-03-30 2017-02-08 Илья Александрович Марков Рекомбинантная плазмида pFM-IFN-17, обеспечивающая экспрессию интерферона альфа-2b человека, рекомбинантная плазмида pFM-АР, обеспечивающая экспрессию фермента метионинаминопептидазы E. coli, биплазмидный штамм Escherichia coli FM-IFN-АР (pFM-IFN-17, pFM-АР) - продуцент (Met-) рекомбинантного интерферона альфа-2b человека

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN150740B (enExample) * 1978-11-24 1982-12-04 Hoffmann La Roche
EP0085693A1 (en) * 1981-08-14 1983-08-17 A/S Alfred Benzon Subjects relating to human inteferon-alpha subtype proteins and corresponding antibodies
DE3306060A1 (de) * 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps

Also Published As

Publication number Publication date
EP0538300B1 (de) 1994-04-13
HU9300036D0 (en) 1993-04-28
FI930058A0 (fi) 1993-01-08
SK386392A3 (en) 1994-08-10
NO930059D0 (no) 1993-01-08
ATE104348T1 (de) 1994-04-15
AU650893B2 (en) 1994-07-07
CA2084514A1 (en) 1992-01-11
FI930058A7 (fi) 1993-01-08
KR930701601A (ko) 1993-06-12
HUT65846A (en) 1994-07-28
WO1992001055A1 (de) 1992-01-23
CZ386392A3 (en) 1993-08-11
DK0538300T3 (da) 1994-10-10
FI930058L (fi) 1993-01-08
PL297610A1 (enExample) 1992-07-13
AU8208291A (en) 1992-02-04
ES2063515T3 (es) 1995-01-01
EP0538300A1 (de) 1993-04-28
JPH06502987A (ja) 1994-04-07
DE59101397D1 (de) 1994-05-19

Similar Documents

Publication Publication Date Title
NO930059L (no) O-glykosylert ifn-alfa
ES2063278T3 (es) Proteina morfogenetica de hueso.
DE69130614D1 (de) Herbizide, substituierte aryl-haloalkylpyrazole
DE69104777D1 (de) Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen.
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ATE295355T1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
ATE245641T1 (de) Antivirale pyrimidinderivate
NO911600D0 (no) Fremgangsmaate for fremstilling av n-(3-fluor-2-fosfonyl-metoksypropyl)-derivater av heterocykliske purin- og pyrimidinbaser.
NO874955D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heteroaromatiske aminderivater.
MX9203417A (es) Compuestos de diarilo antiateroescleroticos.
DK0979079T3 (da) Anvendelse af tetrahydropyridinderivater til fremstilling af lægemidler til behandling af sygdomme, der medförer en demyelinisering
ZA864263B (en) The use of penicillamine for the treatment of immune deficiency diseases
FI914513A7 (fi) Teikoplaniinin uudet, substituoidut alkyyliamidijohdannaiset
FI892222A0 (fi) Peptidalkoholer med antikoagulantverkan.
NO901631L (no) Fremgangsmaate for fremstilling av 2-substituerte n,n'-ditrimetoksybenzoyl-piperaziner.
BG98238A (bg) Заместени бензотиазолови производни,получаванетоим и приложението им като хербициди
EA200101106A1 (ru) Фармацевтический комплекс
DK0855398T3 (da) Sesquiterpenderivater med antiviral aktivitet
IT1225483B (it) Protesi ortopedica, particolarmente per la testa del femore.
ATE249478T1 (de) Harnstoff- und thioharnstoffderivate von antibiotisch wirksamen glykopeptiden
FR2597105B1 (fr) Derives antibiotiques de la famille des 20-0-acyl-19,20-enolmacrolides
ATE212839T1 (de) Hämoregulatorische verbindungen
ATE10934T1 (de) Peptid, verfahren zu dessen herstellung und dessen verwendung.
IT8819919A0 (it) Procedimento perfezionato per laproduzione di componenti ceramici.
NO903705D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n,n-disubstituerte arylcykloalkylaminer.